Novel oncolytic viruses: riding high on the next wave?
The use of viruses as targeted cancer therapy has shown significant promise, and the list of oncolytic viruses continue to grow. The interest in unexplored viruses as oncolytic agents is a natural corollary to the successes and challenges of those already being examined in the clinical setting. Are these 'new' viruses any more effective than their predecessors? What are the benefits of refining current clinical candidates compared to searching for new ones? This review briefly describes some of these novel oncolytic viruses. It also examines the issues that arise in comparing them to each other. We believe that the viral mechanism of action is a key factor to success and suggest guidelines by which all oncolytic virus candidates could be evaluated.
Stanford
Marianne M
MM
Centre for Cancer Therapeutics, Ottawa Health Research Institute, Ottawa, Ontario, Canada. mstanford@ohri.ca
Bell
John C
JC
Vähä-Koskela
Markus J V
MJ
D000818:Animals; D002986:Clinical Trials as Topic; D015316:Genetic Therapy / Q000379:methods; D005822:Genetic Vectors; D006801:Humans; D009369:Neoplasms / Q000473:pathology / Q000628:therapy*; D050130:Oncolytic Virotherapy / Q000379:methods*; D050504:Oncolytic Viruses; D056189:Viral Tropism; D014779:Virus Replication